WO2022199676A1 - Composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine - Google Patents
Composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine Download PDFInfo
- Publication number
- WO2022199676A1 WO2022199676A1 PCT/CN2022/082894 CN2022082894W WO2022199676A1 WO 2022199676 A1 WO2022199676 A1 WO 2022199676A1 CN 2022082894 W CN2022082894 W CN 2022082894W WO 2022199676 A1 WO2022199676 A1 WO 2022199676A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cancer
- alkoxy
- haloalkyl
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 177
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims abstract description 45
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- -1 cyano, amino Chemical group 0.000 claims description 179
- 125000000217 alkyl group Chemical group 0.000 claims description 152
- 125000000623 heterocyclic group Chemical group 0.000 claims description 104
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 101
- 125000003545 alkoxy group Chemical group 0.000 claims description 99
- 150000003839 salts Chemical class 0.000 claims description 98
- 229910052736 halogen Inorganic materials 0.000 claims description 97
- 150000002367 halogens Chemical class 0.000 claims description 97
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 93
- 125000001072 heteroaryl group Chemical group 0.000 claims description 81
- 125000003118 aryl group Chemical group 0.000 claims description 80
- 125000003342 alkenyl group Chemical group 0.000 claims description 63
- 125000000304 alkynyl group Chemical group 0.000 claims description 61
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 51
- 125000001188 haloalkyl group Chemical group 0.000 claims description 51
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 48
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 46
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 125000004043 oxo group Chemical group O=* 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 206010043515 Throat cancer Diseases 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 8
- 238000010511 deprotection reaction Methods 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 206010005949 Bone cancer Diseases 0.000 claims description 7
- 208000018084 Bone neoplasm Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 7
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 7
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 7
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 206010024612 Lipoma Diseases 0.000 claims description 7
- 201000004404 Neurofibroma Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 7
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 7
- 206010057644 Testis cancer Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 208000002672 hepatitis B Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 201000002313 intestinal cancer Diseases 0.000 claims description 7
- 230000003211 malignant effect Effects 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 230000001850 reproductive effect Effects 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 208000023516 stroke disease Diseases 0.000 claims description 7
- 201000003120 testicular cancer Diseases 0.000 claims description 7
- 201000002510 thyroid cancer Diseases 0.000 claims description 7
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
- 206010046431 Urethral cancer Diseases 0.000 claims description 6
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 6
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 6
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 150000001350 alkyl halides Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 150000003254 radicals Chemical group 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 201000005443 oral cavity cancer Diseases 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 13
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000004949 mass spectrometry Methods 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 28
- 239000000203 mixture Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000006413 ring segment Chemical group 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000003480 eluent Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 125000002619 bicyclic group Chemical group 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 125000000000 cycloalkoxy group Chemical group 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 125000003367 polycyclic group Chemical group 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- 229910052805 deuterium Inorganic materials 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 229910052717 sulfur Chemical group 0.000 description 8
- 239000011593 sulfur Chemical group 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 7
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 7
- 239000001099 ammonium carbonate Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Chemical group 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 5
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 5
- 208000003445 Mouth Neoplasms Diseases 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical group C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 3
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 3
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 3
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009822 protein phosphorylation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- AEKHFLDILSDXBL-BYPYZUCNSA-N (2s)-1-(methylamino)propan-2-ol Chemical compound CNC[C@H](C)O AEKHFLDILSDXBL-BYPYZUCNSA-N 0.000 description 2
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 2
- 241001614181 Phera Species 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- VYPYKCPWNPPBBX-UHFFFAOYSA-N 2-(3-bromophenyl)-1,3-dioxolane Chemical compound BrC1=CC=CC(C2OCCO2)=C1 VYPYKCPWNPPBBX-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical group N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OUAZPCKRSSEQKB-UHFFFAOYSA-N 3-bromo-2-fluorobenzaldehyde Chemical compound FC1=C(Br)C=CC=C1C=O OUAZPCKRSSEQKB-UHFFFAOYSA-N 0.000 description 1
- SZDPZQAPHXPVCN-UHFFFAOYSA-N 3-bromo-2-methoxybenzaldehyde Chemical compound COC1=C(Br)C=CC=C1C=O SZDPZQAPHXPVCN-UHFFFAOYSA-N 0.000 description 1
- HHVUFPUWPWOWOA-UHFFFAOYSA-N 3-bromo-2-methylbenzaldehyde Chemical compound CC1=C(Br)C=CC=C1C=O HHVUFPUWPWOWOA-UHFFFAOYSA-N 0.000 description 1
- WTXXUAHMTVAQHW-UHFFFAOYSA-N 3-bromo-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1Br WTXXUAHMTVAQHW-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- PUJVSTYUTMVCSG-UHFFFAOYSA-N 5-bromo-4-fluoro-1h-pyrrolo[2,3-b]pyridine Chemical compound FC1=C(Br)C=NC2=C1C=CN2 PUJVSTYUTMVCSG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 206010073135 Dedifferentiated liposarcoma Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000010395 Pleomorphic liposarcoma Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 108091008091 TCR signalosome Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- CRHWEIDCXNDTMO-UHFFFAOYSA-N ditert-butylphosphane Chemical compound CC(C)(C)PC(C)(C)C CRHWEIDCXNDTMO-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229940044680 immune agonist Drugs 0.000 description 1
- 239000012651 immune agonist Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 208000024596 kidney oncocytoma Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000005039 renal oncocytoma Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Definitions
- the present disclosure belongs to the field of medicine, and relates to a condensed tetracyclic compound, a preparation method thereof and its application in medicine.
- the present disclosure relates to a fused tetracyclic compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and its use in the preparation of a medicament for inhibiting HPK1.
- Anticancer therapy has entered the era of immunotherapy from chemoradiotherapy, targeted therapy, and immunotherapy.
- the targets of tumor immunotherapy mainly include immune checkpoints, immune agonists, Treg, macrophages, tumor microenvironment metabolites such as IDO, A2AR pathway, and so on.
- hematopoietic progenitor kinase 1 Hematopoietic Progenitor Kinase1, referred to as HPK1; also known as mitogen-activated protein kinase kinase kinase 1 (Mitogen-activated protein kinase kinase kinase 1), referred to as MAP4K1
- HPK1 hematopoietic Progenitor Kinase 1
- mitogen-activated protein kinase kinase kinase 1 Mitogen-activated protein kinase kinase kinase 1
- MAP4K1 mitogen
- TCR activation After TCR activation, it functions as a negative feedback regulation, which is related to T cell exhaustion.
- the well-studied signaling pathway is: after TCR binds to MHC-peptide, LAT is phosphorylated, recruiting GADS-SLP76 complex, resulting in phosphorylation and pathway activation of downstream PLC.
- ZAP70 phosphorylates the Y381 site of HPK1, which binds to the SH2 region of SLP76, thereby phosphorylating the latter's S376 site. Phosphorylation of SLP76S376 recruits 14-3-3, which leads to ubiquitination and disassembly of the entire TCR signalosome.
- HPK1 is considered to be a good immunotherapy target for the following three reasons: (1) HPK1 expression profile is limited to immune cells, and it is safe; (2) HPK1 has multiple functions in different stages of the "cancer-immune cycle". Inhibition of HPK1 can regulate the immunosuppressive function of NK cells, DC cells, and T cells, and can also regulate the activation of B cells, among which T cell activation is the most studied; (3) HPK1 kinase activity is involved in inhibiting anti-cancer immune responses. important in.
- HPK1 expression is associated with T cell exhaustion signatures, including CD3E, PD1, CTLA4, TIM-3, LAG-3 and TIGIT, and high HPK1 expression is associated with shorter survival.
- Analysis of the TCGA PanCancer database revealed a positive correlation between HPK1 (but not other MAP4K family members) expression and PD1.
- HPK1 was upregulated in exhausted T cells, and HPK1, TIM3 and LAG3 were more expressed in PD1-high T cells than in PD1-low T cells.
- HPK1 was down-regulated in CD4+ T cells from patients with systemic lupus erythematosus (SLE), and SLEDAI scores were negatively correlated with HPK1 mRNA levels.
- SLE systemic lupus erythematosus
- SLEDAI scores were negatively correlated with HPK1 mRNA levels.
- the expression of HPK1 was also down-regulated in peripheral blood cells of patients with psoriatic arthritis (PsA).
- HPK1 knockout mice did not have any abnormality in the resting state. Once the TCR is activated, whether it is HPK1 knockout, HPK1 kinase dead (kinase dead) knock-in, or SLP76S376A knock-in mice, the results are similar, and the immune response will be activated. HPK1-deficient mice are more susceptible to experimental autoimmune encephalomyelitis (EAE). HPK1 kinase activity modulates TCR signaling and cytokine secretion in vitro; inhibition of HPK1 alleviates PGE2- and adenosine-mediated immunosuppression.
- EAE experimental autoimmune encephalomyelitis
- HPK1 knockout and kinase inactivation knock-in show that HPK1 mainly acts through kinase activity, but some literatures report that its scaffold also has certain functions, so the idea of drug development to inhibit HPK1 is kinase inhibition. Agent-based, but also some PROTAC molecules.
- the related patents disclosed so far include WO2016205942A1, WO2019238067A1, WO2021013083A1, WO2020103896A1 and WO2021000925A1 and so on.
- Ring A is aryl or heteroaryl
- Ring B is phenyl or 5- or 6-membered heteroaryl
- G 1 is CR 1 or nitrogen atom
- G 2 is CR 2 or nitrogen atom
- G 6 is selected from C(O), CR 6a R 6b , NR 6c and oxygen atoms;
- G 7 is selected from C(O), CR 7a R 7b , NR 7c and oxygen atoms;
- R 6a , R 6b , R 7a and R 7b are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino , nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, Aryl and heteroaryl are each independently optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, substituted with one or more substituents of cycloalkyl, heterocyclyl, aryl and heteroaryl;
- R 0 , R 6c and R 7c are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group base;
- Each R a is the same or different, and each is independently selected from a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) r NR m R n , -OR p , nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, alkoxy, cyclic Alkyl, heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro , substituted with one or more substituents in hydroxy, oxo, hydroxyalkyl, cycloalkyl, heterocyclyl,
- R a and ring B form a condensed ring optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino , nitro, hydroxyl, oxo, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl substituted with one or more groups, wherein said alkyl, alkenyl, alkynyl, Alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, oxo, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl substituted with one or more substituents;
- R', R 1 and R 2 are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -NR d Re , -OR g , -(CO)R f , -(CO)NR d Re , -(CO)OR g , -SO 2 R f , -SO 2 NR d Re , -NR h (CO )R f , -NR h (CO)NR d Re , -NR h (CO)OR g , -NR h SO 2 R f , -NR h SO 2 NR d R e , nitro, hydroxyl, hydroxyalkyl , cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkyny
- R m , R n , R p , R d , Re , R f , R g , Rh , R d2 , Re2 , R f2 , R g2 and R h2 are the same or different, and are each independently selected from hydrogen atoms , alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, hetero Cyclic, aryl, and heteroaryl are each independently optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxy substituted with one or more substituents of alkyl, cycloalkyl, heterocyclyl, aryl and
- heterocyclyl group optionally selected from halogen, alkyl, alkenyl, alkyne one or more of radical, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, oxo, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl substituted groups wherein said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, alkyl, alkenyl , alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and one or more substitution
- p 0, 1, 2, 3, or 4;
- q 0, 1, 2, 3 or 4;
- r 0, 1, 2, 3 or 4.
- the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II) or (III) or a pharmaceutically acceptable salt thereof:
- G 3 is CR 3 or nitrogen atom
- G 5 is CR 5 or nitrogen atom
- R 3 and R 5 are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxyl, Hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl each independently optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocycle substituted with one or more substituents in aryl, aryl and heteroaryl;
- R 4a and R 4b are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) r NR m R n , -OR p , nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, alkoxy , cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, Substituted with one or more substituents of nitro, hydroxy, oxo, hydroxyalkyl, cycloalkyl
- Each R is the same or different and is independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl , cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl substituted with one or more substituents in the radical and heteroaryl; or
- R q is selected from hydrogen atom, alkyl group, alkenyl group, alkynyl group, haloalkyl group, hydroxyalkyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group;
- n 0, 1, 2, 3, 4, 5 or 6;
- Rings A , G1 , G2, G6 , G7, R0, Rm, Rn, Rp , R ' , r and q are as defined in general formula (I).
- the compound represented by the general formula (I), (II) or (III) or a pharmaceutically acceptable salt thereof is the compound represented by the general formula (IV) or (V) or Its pharmaceutically acceptable salts:
- Rings A , G1, G6 , G7, R0, R2, R3 , R4a , R4b , R5, Rq , R', R, q and n are of formula ( II ) or (III) ) as defined in .
- the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is the compound represented by the general formula (VI) or a pharmaceutically acceptable salt thereof:
- t 0, 1, 2 or 3;
- Ring A , Ring B, Rd , Re , G1 , G2, G6 , G7, R0, Ra , R' and p are as defined in general formula (I ) .
- the compound represented by the general formula (I), (II), (III), (IV), (V) or (VI) or a pharmaceutically acceptable salt thereof wherein- G7- G6- is selected from -O- CHR6a- , -CHR7a -O-, -NR7c - CHR6a- , -CHR7a - NR6c- , -C(O) -NR6c- and -NR 7c -C(O)-, R 6a , R 7a , R 6c and R 7c are as defined in general formula (I); preferably, -G 7 -G 6 - is selected from -O-CH 2 -, -CH 2 - O- , -NH-CH2-, -CH2 -NH-, -C(O)-NH- and -NH-C(O)-; more preferably, -G7 - G6- is- O-CH 2 -.
- R 1 is selected from hydrogen atom, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl;
- R 1 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; more preferably hydrogen atom.
- the compound represented by the general formula (I), (II), (III), (IV), (V) or (VI) or a pharmaceutically acceptable salt thereof wherein G 1 is CR 1 , and R 1 is as defined in general formula (I); preferably, G 1 is CR 1 , and R 1 is selected from hydrogen atom, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl; further preferably, G 1 is CR 1 , and R 1 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; more preferably, G 1 is CH.
- R 2 is selected from hydrogen atom, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl;
- R 2 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; more preferably hydrogen atom.
- R 3 is selected from hydrogen atom, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl;
- R 3 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; more preferably hydrogen atom.
- R 5 is selected from hydrogen atom, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl;
- R 5 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; more preferably hydrogen atom or methyl.
- the compound represented by the general formula (II) or (III) or a pharmaceutically acceptable salt thereof wherein R 5 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 alkoxy; preferably, R 5 is selected from hydrogen atom, F, methyl and methoxy.
- the compound represented by the general formula (I), (II), (III), (IV), (V) or (VI) or a pharmaceutically acceptable salt thereof wherein each R' is the same or different, and is each independently selected from C 1-6 alkyl, C 1-6 haloalkyl or -(CO)NR d Re , where R d and Re are as defined in general formula (I);
- R d and R e are the same or different, and are each independently selected from a hydrogen atom, a C 1-6 alkyl group, a C 1-6 haloalkyl group, and a C 1-6 hydroxyalkyl group, or R d and R e are combined with The nitrogen atoms to which they are attached together form a 3- to 8-membered heterocyclic group optionally selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1- Substituted with one or more groups in 6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl;
- R d and R e are the same or different, and are each independently selected from a hydrogen atom, a C 1-6 alkyl group, a C 1-6 haloalkyl group and a C 1-6 hydroxyalkyl group, or R d and R e together with the nitrogen atoms to which they are attached form an azetidinyl group optionally selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, cyano, hydroxy and One or more groups in the C 1-6 hydroxyalkyl group are substituted.
- the compound represented by the general formula (I), (II), (III), (IV), (V) or (VI) or a pharmaceutically acceptable salt thereof wherein each R' is the same or different, and is each independently C 1-6 alkyl or -(CO)NR d Re , where R d and Re are as defined in general formula (I);
- each R' is the same or different, and each is independently a C 1-6 alkyl group or -(CO)NR d Re , and R d and Re are the same or different, and each is independently selected from a hydrogen atom, C 1-6 alkyl and C 1-6 hydroxyalkyl, or R d and R e together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocyclic group optionally replaced by a or multiple hydroxyl substitutions;
- each R' is the same or different, and each independently is C 1-6 alkyl or -(CO)NR d Re , R d and Re are the same or different, and each is independently selected from C 1- 6 alkyl and C 1-6 hydroxyalkyl, or R d and R e together with the nitrogen atom to which they are attached form an azetidinyl group optionally substituted by one or more hydroxyl groups replace.
- the compound represented by the general formula (II) or (IV) or a pharmaceutically acceptable salt thereof wherein R 4a and R 4b are the same or different, and are each independently selected from hydrogen atoms , halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, -(CH 2 ) r NR m R n , hydroxyl and C 1-6 hydroxyalkyl, wherein said C 1-6 alkyl and C 1-6 alkoxy are each independently optionally selected from halogen, C 1-6 alkoxy, C 1-6 haloalkane substituted with one or more substituents of oxy, cyano, amino, hydroxy and C 1-6 hydroxyalkyl, R m , R n and r are as defined in general formula (II);
- R 4a and R 4b are the same or different, and each is independently selected from a hydrogen atom, a C 1-6 alkyl group, a C 1-6 haloalkyl and C 1-6 hydroxyalkyl, wherein said C 1-6 alkyl is optionally selected from C 1-6 alkoxy, C 1-6 haloalkoxy, cyano and amino substituted by one or more substituents; or R and R together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocyclic group optionally selected from halogen, C One of 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl, oxo and C 1-6 hydroxyalkyl or Multiple group substitution; r is 0, 1 or 2;
- one of R 4a and R 4b is -(CH 2 ) r NR m R n , the other is a hydrogen atom, R m and R n are the same or different, and are independently selected from hydrogen atoms, C 1- 6 alkyl and C 1-6 haloalkyl ; or R and R together with the nitrogen atom to which they are attached form a piperazine ring optionally selected from halogen, C 1-6 alkyl and C One or more of the 1-6 haloalkyl groups are substituted; r is 0 or 1.
- the compound represented by general formula (II) or (IV) or a pharmaceutically acceptable salt thereof wherein one of R 4a and R 4b is -(CH 2 ) r NR m R n , the other is a hydrogen atom or a C 1-6 alkyl group, R m and R n are the same or different, and are each independently a C 1-6 alkyl group; or R m and R n together with the nitrogen atom to which they are attached A piperazine ring is formed, which is optionally substituted with one or more C1-6 alkyl groups; r is 0 or 1.
- the compound represented by the general formula (II) or (IV) or a pharmaceutically acceptable salt thereof wherein R 4a and R 4b are the same or different, and are each independently selected from hydrogen atoms , halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, -(CH 2 ) r NR m R n , hydroxyl and C 1-6 hydroxyalkyl, wherein said C 1-6 alkyl and C 1-6 alkoxy are each independently optionally selected from halogen, C 1-6 alkoxy, C 1-6 haloalkane substituted by one or more substituents of oxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl, and at least one of R 4a and R 4b is -(CH 2 ) r NR m R n , R m and R n are the same or different, and
- the compound represented by the general formula (II) or (IV) or a pharmaceutically acceptable salt thereof wherein R 4a is piperazinyl, and the piperazinyl is optionally C 1 -6 alkyl substitution; and/or R 4b is a hydrogen atom.
- the compound represented by the general formula (II) or (IV) or a pharmaceutically acceptable salt thereof wherein R 4a is 4-methylpiperazin-1-yl or 4-ethyl and/or R 4b is a hydrogen atom or a methyl group.
- the compound represented by the general formula (III) or (V) or a pharmaceutically acceptable salt thereof wherein each R is the same or different, and is independently selected from hydrogen atom, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, hydroxyl and C 1-6 hydroxyalkyl;
- each R is the same or different, and each is independently selected from a hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl.
- the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof wherein -G 7 -G 6 - is selected from -O-CH 2 -, -CH 2 -O -, -NH-CH 2 -, -CH 2 -NH-, -C(O)-NH- and -NH-C(O)-; Ring A is phenyl or pyrazolyl; G 1 is CR 1 , R 1 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; G 2 is CR 2 , R 2 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkane group; G 3 is CR 3 , R 3 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; G 5 is CR 5 , R 5 is selected from hydrogen atom, halogen, C 1-6 Al
- the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof wherein -G 7 -G 6 - is -O-CH 2 -; ring A is phenyl or Pyrazolyl; G 1 is CR 1 , R 1 is hydrogen atom; G 2 is CR 2 , R 2 is hydrogen atom; G 3 is CR 3 , R 3 is hydrogen atom; G 5 is CR 5 , and R 5 is selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 alkoxy; R 0 is hydrogen atom; q is 1; each R' is C 1-6 alkyl or -(CO)NR d Re , R d and R e are the same or different, and are each independently selected from a hydrogen atom, a C 1-6 alkyl group, and a C 1-6 hydroxyalkyl group, or R d and R e together with the nitrogen atom to which they are attached form 3 to 8-member
- Typical compounds of the present disclosure include, but are not limited to:
- Another aspect of the present disclosure relates to a compound of formula (IA) or a salt thereof,
- R w is an amino protecting group; preferably Ts;
- Ring A , Ring B, G1 , G2, G6 , G7, R', Ra , p and q are as defined in general formula (I).
- Another aspect of the present disclosure relates to a compound of general formula (IIA) or (IIIA) or a salt thereof,
- R w is an amino protecting group; preferably Ts;
- Rings A , G1 , G2, G3 , G5, G6 , G7 , R', R4a , R4b , Rq , R, n and q are as in general formula (II) or (III) definition.
- Another aspect of the present disclosure relates to a compound of general formula (IVA) or (VA) or a salt thereof,
- R w is an amino protecting group; preferably Ts;
- Rings A , G1 , R2, R3 , R5 , G6 , G7, R', R4a , R4b , Rq , R, n and q are as in general formula (IV) or (V) definition.
- Another aspect of the present disclosure relates to a compound of formula (VIA) or a salt thereof,
- R w is an amino protecting group; preferably Ts;
- Ring A , Ring B, Rd , Re , G1 , G2, G6 , G7, Ra , R', t and p are as defined in general formula (VI).
- Typical intermediate compounds of the present disclosure include, but are not limited to:
- Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IA) or its salt is subjected to deprotection reaction to obtain the compound of general formula (I) or its pharmaceutically acceptable salt;
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Ring A , Ring B, G1 , G2, G6 , G7, R', Ra , p and q are as defined in general formula (I).
- Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II) or (III) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IIA) or a salt thereof is subjected to a deprotection reaction to obtain a compound of general formula (II) or a pharmaceutically acceptable salt thereof; or
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Rings A , G1 , G2, G3 , G5, G6 , G7 , R', R4a , R4b , Rq , R, n and q are as in general formula (II) or (III) definition.
- Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IV) or (V) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IVA) or a salt thereof is subjected to a deprotection reaction to obtain a compound of general formula (IV) or a pharmaceutically acceptable salt thereof; or
- the compound of general formula (VA) or its salt is subjected to deprotection reaction to obtain the compound of general formula (V) or its pharmaceutically acceptable salt;
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Rings A , G1 , R2, R3 , R5 , G6 , G7, R', R4a , R4b , Rq , R, n and q are as in general formula (IV) or (V) definition.
- Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (VIA) or its salt is subjected to deprotection reaction to obtain the compound of general formula (VI) or its pharmaceutically acceptable salt;
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Ring A , Ring B, Rd , Re , G1 , G2, G6 , G7, Ra , R', t and p are as defined in general formula (VI).
- Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising:
- Q is halogen or hydroxyl, preferably hydroxyl
- Ring A , Ring B, Rd , Re , G1 , G2, G6 , G7, Ra , R0 , R', t and p are as defined in general formula (VI).
- compositions comprising any of the formulas (I), (II), (III), (IV), (V), (VI) or Table A of the present disclosure
- the present disclosure further relates to a compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a medicament comprising the same Use of the composition in the manufacture of a medicament for inhibiting HPK1.
- the present disclosure further relates to a compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a medicament comprising the same Use of the composition in the preparation of a medicament for treating and/or preventing a disease or condition by inhibiting HPK1;
- the disease or condition is preferably selected from cancer, autoimmune disease, inflammatory disease, infectious disease, cardiac Use in the medicament of a disease or condition of vascular disease, neurodegenerative disease, diabetes and reproductive disorders, preferably, said disease or condition is selected from cancer, allergy, asthma, sepsis, HIV infection, hepatitis B virus infection, deficiency blood, atherosclerosis, stroke and Alzheimer's disease;
- the cancer is preferably selected from brain cancer, thyroid cancer, head and neck cancer, throat cancer, oral cancer, salivary gland cancer, esophagus cancer, stomach cancer, lung cancer, liver cancer, Kidney cancer, pancreatic cancer, bile duct cancer, colorectal
- the present disclosure further relates to a compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a medicament comprising the same
- a composition in the manufacture of a medicament for the treatment and/or prevention of diseases or conditions of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular diseases, neurodegenerative diseases, diabetes and reproductive disorders
- the disease or condition is selected from cancer, allergy, asthma, sepsis, HIV infection, hepatitis B virus infection, ischemia, atherosclerosis, stroke and Alzheimer's disease
- the cancer is preferably selected from Brain cancer, thyroid cancer, head and neck cancer, throat cancer, oral cancer, salivary gland cancer, esophagus cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, bile duct cancer, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, Urothelial cancer, urethral cancer, bladder cancer, breast cancer,
- the present disclosure further relates to a method of inhibiting HPK1, comprising administering to a patient in need thereof a therapeutically effective amount of formula (I), (II), (III), (IV), (V), (VI) or Table A
- a method of inhibiting HPK1 comprising administering to a patient in need thereof a therapeutically effective amount of formula (I), (II), (III), (IV), (V), (VI) or Table A
- the present disclosure further relates to a method of treating and/or preventing a disease or disorder by inhibiting HPK1, comprising administering to a patient in need thereof a therapeutically effective amount of formula (I), (II), (III), (IV), (V), (VI) or a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- said disease or condition is preferably selected from cancer, autoimmune disease, inflammatory disease, infectious disease, cardiovascular disease, neurodegenerative disease, diabetes and reproductive disorders; preferably, said disease or condition is selected from Cancer, allergy, asthma, sepsis, HIV infection, hepatitis B virus infection, ischemia, atherosclerosis, stroke and Alzheimer's disease; the cancer is preferably selected from brain cancer, thyroid cancer, head and neck cancer, throat cancer Cancer, oral cancer, salivary gland cancer, esophagus cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, bile duct cancer, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, urothelial cancer, urinary tract cancer, bladder cancer , Breast cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, leukemia, lymphoma, multiple myeloma, skin cancer, malignant lipoma, bone cancer, soft tissue sarcoma, neurofibroma
- the present disclosure further relates to a method of treating and/or preventing a disease or condition of cancer, autoimmune disease, inflammatory disease, infectious disease, cardiovascular disease, neurodegenerative disease, diabetes, and reproductive disorders, comprising administering the A compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a compound thereof, in a therapeutically effective amount for a patient
- said disease or condition is selected from cancer, allergy, asthma, sepsis, HIV infection, hepatitis B virus infection, ischemia, atherosclerosis, stroke and Alzheimer's disease; said The cancer is preferably selected from brain cancer, thyroid cancer, head and neck cancer, throat cancer, oral cavity cancer, salivary gland cancer, esophagus cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, bile duct cancer, colorectal cancer, small bowel cancer, gastrointestinal cancer Tracheal stromal tumor, urothelial cancer,
- the present disclosure further relates to a compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a compound including the same A pharmaceutical composition for use as a medicament.
- the present disclosure further relates to a compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a compound including the same A pharmaceutical composition for use as a drug that inhibits HPK1.
- the present disclosure further relates to a compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a compound including the same
- the disease or condition is preferably selected from cancer, autoimmune disease, inflammatory disease, infection Sexual diseases, cardiovascular diseases, neurodegenerative diseases, diabetes and reproductive disorders;
- the disease or condition is selected from cancer, allergy, asthma, sepsis, HIV infection, hepatitis B virus infection, ischemia, atherosclerosis Sclerosis, stroke and Alzheimer's disease
- the cancer is preferably selected from brain cancer, thyroid cancer, head and neck cancer, throat cancer, oral cancer, salivary gland cancer, esophagus cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer , Cholangiocarcinoma, colorectal cancer, small bowel cancer,
- the present disclosure further relates to a compound of general formula (I), (II), (III), (IV), (V), (VI) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a compound including the same
- Pharmaceutical compositions for the treatment and/or prevention of diseases or conditions of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular diseases, neurodegenerative diseases, diabetes and reproductive disorders preferably, said The disease or condition is selected from cancer, allergy, asthma, sepsis, HIV infection, hepatitis B virus infection, ischemia, atherosclerosis, stroke and Alzheimer's disease; the cancer is preferably selected from brain cancer, thyroid Cancer, head and neck cancer, throat cancer, oral cancer, salivary gland cancer, esophagus cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, bile duct cancer, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, urothelial cancer , urethral cancer, bladder cancer, breast cancer, ovarian cancer, endometrial
- the brain cancer described in the present disclosure is selected from glioblastoma multiforme or neuroblastoma; soft tissue cancer is selected from fibrosarcoma, gastrointestinal sarcoma, rhabdomyosarcoma, leiomyosarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, malignant fibrous histiocytoma, round cell sarcoma, and synovial sarcoma; lymphoma selected from Hodgkin's disease and non-Hodgkin's lymphoma (eg, mantle cell lymphoma, diffuse large B-cell lymphoma , follicular center lymphoma, marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma and peripheral T-cell lymphoma); liver cancer is preferably hepatocellular carcinoma; lung cancer is selected from non-small cell lung cancer (NSCLC) (eg squamous cell carcinoma)
- the colorectal cancer described in the present disclosure is also called colorectal cancer, preferably colon cancer or rectal cancer; the glioma is preferably glioblastoma.
- the active compounds can be formulated in a form suitable for administration by any suitable route, and the compositions of the present disclosure can be formulated by conventional methods using one or more pharmaceutically acceptable carriers. Accordingly, the active compounds of the present disclosure can be formulated in various dosage forms for oral administration, injection (eg, intravenous, intramuscular, or subcutaneous) administration, inhalation or insufflation.
- the compounds of the present disclosure may also be formulated in dosage forms such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injectable solutions, dispersible powders or granules, suppositories, lozenges or syrups.
- the active compound is preferably presented in a unit dose or in a form that the patient can self-administer in a single dose.
- a unit dose of a compound or composition of the present disclosure may be expressed as a tablet, capsule, cachet, vial, powder, granule, lozenge, suppository, reconstituted powder, or liquid.
- a suitable unit dose may be 0.1 to 1000 mg.
- the pharmaceutical composition of the present disclosure may contain one or more excipients selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients Wait.
- the composition may contain from 0.1 to 99% by weight of active compound.
- Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients suitable for the manufacture of tablets.
- excipients may be inert excipients, granulating agents, disintegrating agents, binders and lubricants. These tablets may be uncoated or they may be coated by known techniques to mask the taste of the drug or to delay disintegration and absorption in the gastrointestinal tract, thereby providing sustained release over an extended period of time.
- Oral formulations can also be presented in soft gelatin capsules in which the active ingredient is mixed with an inert solid diluent or in which the active ingredient is mixed with a water-soluble or oily vehicle.
- Aqueous suspensions contain the active substances in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending, dispersing or wetting agents.
- the aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
- Oily suspensions can be formulated by suspending the active ingredient in vegetable or mineral oils.
- the oily suspensions may contain thickening agents.
- the aforementioned sweetening and flavoring agents may be added to provide a palatable preparation. These compositions can be preserved by adding antioxidants.
- compositions of the present disclosure may also be in the form of oil-in-water emulsions.
- the oily phase can be vegetable oil, or mineral oil or a mixture thereof.
- Suitable emulsifying agents may be naturally occurring phospholipids, and the emulsions may also contain sweetening, flavoring, preservative and antioxidant agents.
- Such formulations may also contain a demulcent, a preservative, a coloring agent and an antioxidant.
- compositions of the present disclosure may be in the form of sterile injectable aqueous solutions.
- acceptable vehicles or solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- a sterile injectable preparation can be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oily phase.
- the injectable solution or microemulsion can be injected into the bloodstream of a patient by local bulk injection.
- solutions and microemulsions are preferably administered in a manner that maintains a constant circulating concentration of the compounds of the present disclosure.
- a continuous intravenous drug delivery device can be used.
- An example of such a device is the Deltec CADD-PLUS.TM.5400 IV pump.
- compositions of the present disclosure may be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent.
- sterile fixed oils are conveniently employed as a solvent or suspending medium. For this purpose, any blending and fixing oil can be used.
- fatty acids are also available in the preparation of injectables.
- the compounds of the present disclosure can be administered in the form of suppositories for rectal administration.
- These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and therefore will melt in the rectum to release the drug.
- the compounds of the present disclosure can be administered by the addition of water to prepare dispersible powders and granules for aqueous suspension.
- These pharmaceutical compositions can be prepared by admixing the active ingredient with a dispersing or wetting agent, suspending agent or one or more preservatives.
- the dosage of a drug to be administered depends on a variety of factors including, but not limited to, the following factors: the activity of the particular compound used, the age of the patient, the weight of the patient, the health of the patient, the behavior of the patient , patient's diet, time of administration, mode of administration, rate of excretion, combination of drugs, severity of disease, etc.; in addition, optimal treatment mode such as mode of treatment, daily dose of compound or pharmaceutically acceptable salt Species can be verified against conventional treatment protocols.
- alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably 1 to 12 (eg 1, 2, 3, 4, 5, 6 , 7, 8, 9, 10, 11 and 12) carbon atoms (ie C 1-12 alkyl), more preferably alkyl having 1 to 6 carbon atoms (ie C 1-6 alkyl) ).
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2 -methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl,
- lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-Methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylpropyl butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl base, 2,3-dimethylbutyl, etc.
- Alkyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, the substituent preferably being selected from the group consisting of D atom, halogen, alkyl, alkoxy, haloalkyl , one or more of haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl heteroaryl indivual.
- alkylene refers to a saturated straight or branched chain aliphatic hydrocarbon group, which is a residue derived by removing two hydrogen atoms from the same carbon atom or two different carbon atoms of the parent alkane, which is a residue containing 1 straight or branched chain groups of up to 20 carbon atoms, preferably having 1 to 12 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms ( That is, a C 1-12 alkylene group), more preferably an alkylene group having 1 to 6 carbon atoms (ie, a C 1-6 alkylene group).
- 1 to 12 eg 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
- Non-limiting examples of alkylene groups include, but are not limited to, methylene ( -CH2- ), 1,1-ethylene (-CH( CH3 )-), 1,2-ethylene (-CH 2 CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene base (-CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -) and the like.
- the alkylene group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from the group consisting of alkenyl, alkynyl, alkoxy, haloalkoxy, Cycloalkyloxy, heterocyclyloxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy one or more of oxo, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo.
- alkenyl refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein the alkyl group is as defined above, preferably having 2 to 12 (eg 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms (ie C 2-12 alkenyl), more preferably alkenyl having 2 to 6 carbon atoms (ie C 2-6 alkenyl).
- Non-limiting examples include: vinyl, propenyl, isopropenyl, butenyl, and the like.
- Alkenyl can be substituted or unsubstituted, when substituted, the substituent is preferably selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl one or more of , cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
- alkynyl refers to an alkyl group having at least one carbon-carbon triple bond in the molecule, wherein alkyl is as defined above. Preferably have 2 to 12 (eg 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms (ie C 2-12 alkynyl), more preferably have 2 to 6 Alkynyl of carbon atoms (ie C 2-6 alkynyl).
- Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
- Alkynyl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl one or more of , cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 14 (eg 3, 4, 5, 6 , 7, 8, 9, 10, 11, 12, 13 and 14) carbon atoms (i.e. 3 to 14 membered cycloalkyl), preferably 3 to 8 (e.g. 3, 4, 5, 6, 7 and 8) ) carbon atoms (ie 3 to 8 membered cycloalkyl), more preferably 3 to 6 carbon atoms (ie 3 to 6 membered cycloalkyl).
- 3 to 14 eg 3, 4, 5, 6 , 7, 8, 9, 10, 11, 12, 13 and 14
- 3 to 8 e.g. 3, 4, 5, 6, 7 and 8
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- Polycyclic cycloalkyl groups include spirocycloalkyl groups, fused cycloalkyl groups and bridged cycloalkyl groups.
- spirocycloalkyl refers to a 5- to 20-membered polycyclic group having one carbon atom (called a spiro atom) shared between the monocyclic rings, which may contain one or more double bonds. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan (eg 7, 8, 9 or 10 yuan). According to the number of shared spiro atoms between the rings, spirocycloalkyl groups are classified as mono- or poly-spirocycloalkyl groups (eg, bis-spirocycloalkyl groups), preferably mono-spirocycloalkyl groups and bis-spirocycloalkyl groups base.
- mono- or poly-spirocycloalkyl groups eg, bis-spirocycloalkyl groups
- spirocycloalkyl include:
- fused cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or more rings. Multiple double bonds. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan (eg 7, 8, 9 or 10 yuan).
- bicyclic or polycyclic (such as tricyclic, tetracyclic) fused cycloalkyl groups preferably bicyclic or tricyclic, more preferably 3-membered/4-membered, 3-membered/5-membered, 3-membered/membered 6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan , 6-member/3-member, 6-member/4-member, 6-member/5-member, 6-member/6-member, 6-member/7-member, 7-member/5-member or 7-member/6-membered bicyclic fused cycloalkyl.
- fused cycloalkyl groups include:
- bridged cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members, any two rings sharing two non-directly attached carbon atoms, which may contain one or more double bonds. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan (eg 7, 8, 9 or 10 yuan). According to the number of constituent rings, it can be divided into bicyclic or polycyclic (eg tricyclic, tetracyclic) bridged cycloalkyl groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
- bridged cycloalkyl include:
- the cycloalkyl ring includes a cycloalkyl (including monocyclic, spiro, fused and bridged) as described above fused to an aryl, heteroaryl or heterocycloalkyl ring where it is attached to the parent structure Rings together are cycloalkyl, non-limiting examples include etc.; preferably
- Cycloalkyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, the substituents are preferably selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy One or more of hydroxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl.
- alkoxy refers to -O-(alkyl), wherein alkyl is as defined above.
- alkoxy groups include: methoxy, ethoxy, propoxy, and butoxy.
- Alkoxy can be optionally substituted or unsubstituted, when substituted, the substituent is preferably selected from D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy group, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic substituent comprising 3 to 20 (eg 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e. 3 to 20 membered heterocyclyl), wherein one or more of the ring atoms is a heteroatom selected from nitrogen, oxygen and sulfur, so Said sulfur may optionally be oxo (ie, to form a sulfoxide or sulfone), but does not include ring moieties of -O-O-, -O-S- or -S-S-, the remaining ring atoms being carbon.
- It preferably contains 3 to 14 (eg 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14) ring atoms (ie 3 to 14 membered heterocyclyl), of which 1 to 4 (eg 1, 2, 3 and 4) are heteroatoms; more preferably 3 to 8 ring atoms (eg 3, 4, 5, 6, 7 and 8) are included (ie 3 to 8 membered heterocyclyl) or 6 to 14 ring atoms (e.g. 6, 7, 8, 9, 10, 11, 12, 13 and 14) of which 1-3 are heteroatoms (e.g.
- Non-limiting examples of monocyclic heterocyclyl groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholine base, homopiperazinyl, etc.
- Polycyclic heterocyclyls include spiro heterocyclyls, fused heterocyclyls and bridged heterocyclyls.
- spiroheterocyclyl refers to a 5- to 20-membered polycyclic heterocyclic group with one atom (called a spiro atom) shared between the monocyclic rings, wherein one or more ring atoms are heterocyclic groups selected from nitrogen, oxygen and sulfur.
- the sulfur may optionally be oxo (ie to form a sulfoxide or sulfone), and the remaining ring atoms are carbon. It may contain one or more double bonds.
- Spiroheterocyclyls are classified into mono- or poly-spiroheterocyclyls (eg, bis-spiroheterocyclyls) according to the number of spiro atoms shared between the rings, preferably mono-spiroheterocyclyls and bis-spiroheterocyclyls base.
- spiroheterocyclyl include:
- fused heterocyclyl refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, and one or more of the rings may contain one or more Double bonds in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur, which may be optionally oxo (ie, to form a sulfoxide or sulfone), and the remaining ring atoms are carbon.
- it is 6 to 14 membered (eg 6, 7, 8, 9, 10, 11, 12, 13 and 14 membered) (ie 6 to 14 membered fused heterocyclic group), more preferably 7 to 10 membered (eg 7, 8, 9 or 10 membered) (ie 7 to 10 membered fused heterocyclyl).
- bicyclic or polycyclic such as tricyclic, tetracyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 3-membered/4-membered, 3-membered/5-membered, 3-membered/membered 6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan , 6-membered/3-membered, 6-membered/4-membered, 6-membered/5-membered, 6-membered/6-membered, 6-membered/7-membered, 7-membered/5-membered or 7-membered/6-membered bicyclic fused heterocycl
- bridged heterocyclyl refers to a 5- to 20-membered, polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, in which one or more ring atoms is a heteroatom selected from nitrogen, oxygen, and sulfur, which may optionally be oxo (ie, to form a sulfoxide or sulfone), and the remaining ring atoms are carbon.
- it is 6 to 14 membered (eg 6, 7, 8, 9, 10, 11, 12, 13 and 14 membered) (ie 6 to 14 membered bridged heterocyclyl), more preferably 7 to 10 membered (eg 7, 8, 9 or 10 membered) (ie, a 7- to 10-membered bridged heterocyclyl).
- 6 to 14 membered eg 6, 7, 8, 9, 10, 11, 12, 13 and 14 membered
- 7 to 10 membered eg 7, 8, 9 or 10 membered
- a 7- to 10-membered bridged heterocyclyl ie 6 to 14 membered bridged bridged bridged heterocyclyl
- bridged heterocyclyl groups include:
- the heterocyclyl ring includes a heterocyclyl group (including monocyclic, spiroheterocycle, fused heterocycle and bridged heterocycle) as described above fused to an aryl, heteroaryl or cycloalkyl ring, wherein the
- the rings to which the structure is attached are heterocyclyl, non-limiting examples of which include:
- Heterocyclyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, preferably selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy One or more of hydroxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl.
- aryl refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic are rings that share adjacent pairs of carbon atoms) groups having a conjugated pi-electron system, preferably 6 to 10 membered , such as phenyl and naphthyl.
- the aryl ring includes an aryl ring as described above fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring linked to the parent structure is an aryl ring, non-limiting examples of which include :
- Aryl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, preferably selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy One or more of hydroxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl.
- heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms (eg 1, 2, 3 and 4), 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen.
- Heteroaryl is preferably 5 to 10 membered (eg 5, 6, 7, 8, 9 or 10 membered) (ie 5 to 10 membered heteroaryl), more preferably 5 or 6 membered (ie 5 or 6 membered) heteroaryl), for example furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl Wait.
- the heteroaryl ring includes a heteroaryl fused to an aryl, heterocyclyl or cycloalkyl ring as described above, wherein the ring linked to the parent structure is a heteroaryl ring, non-limiting examples of which include :
- Heteroaryl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, preferably selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy One or more of hydroxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl.
- cycloalkyl, heterocyclyl, aryl and heteroaryl groups include residues derived by removing one hydrogen atom from the parent ring atom, or removing two hydrogen atoms from the same ring atom or two different ring atoms of the parent
- residues from which atoms are derived are "divalent cycloalkyl", "divalent heterocyclyl", “arylene” and "heteroarylene”.
- amino protecting group is used to protect the amino group with a group that is easy to remove in order to keep the amino group unchanged when the other part of the molecule is reacted.
- Non-limiting examples include (trimethylsilyl)ethoxymethyl (SEM), tetrahydropyranyl, t-butoxycarbonyl, acetyl, benzyl, allyl, p-methylbenzenesulfonyl (Ts ) and p-methoxybenzyl, etc.
- SEM trimethylsilyl)ethoxymethyl
- Ts p-methylbenzenesulfonyl
- Ts p-methoxybenzyl
- hydroxy protecting group refers to a hydroxy derivative commonly used to block or protect a hydroxy group while reacting on other functional groups of a compound.
- the hydroxyl protecting group can be triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl, methyl , tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl, p-nitro benzoyl.
- cycloalkyloxy refers to cycloalkyl-O-, wherein cycloalkyl is as defined above.
- heterocyclyloxy refers to heterocyclyl-O-, wherein heterocyclyl is as defined above.
- aryloxy refers to aryl-O-, wherein aryl is as defined above.
- heteroaryloxy refers to heteroaryl-O-, wherein heteroaryl is as defined above.
- alkylthio refers to alkyl-S-, wherein alkyl is as defined above.
- haloalkyl refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
- haloalkoxy refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
- deuterated alkyl refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
- hydroxyalkyl refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
- halogen refers to fluorine, chlorine, bromine or iodine.
- hydroxy refers to -OH.
- thiol refers to -SH.
- amino refers to -NH2 .
- cyano refers to -CN.
- nitro refers to -NO2 .
- carboxylate refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O )O-, wherein alkyl and cycloalkyl are as defined above.
- Ts refers to p-toluenesulfonyl.
- stereoisomer refers to isomers that are structurally identical but differ in the arrangement of the atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (e.g. racemates, mixtures of diastereomers) . Substituents in the compounds of the present disclosure may have additional asymmetric atoms.
- Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers, and (D)- and (D)- and (+)-isomers can be prepared by chiral synthesis, chiral reagents, or other conventional techniques (L)-isomer.
- An isomer of a certain compound of the present disclosure can be prepared by asymmetric synthesis or chiral auxiliaries, or, when the molecule contains basic functional groups (such as amino groups) or acidic functional groups (such as carboxyl groups), with appropriate optical Active acids or bases form diastereomeric salts, which are then resolved by conventional methods known in the art to yield the pure isomers. Furthermore, the separation of enantiomers and diastereomers is usually accomplished by chromatography.
- the bond Indicates an unspecified configuration, i.e. if a chiral isomer exists in the chemical structure, the bond can be or both Two configurations. For all carbon-carbon double bonds, even if only one configuration is named, both Z and E forms are included.
- tautomer or tautomeric form refers to structural isomers of different energies that are interconvertible via a low energy barrier.
- proton tautomers also known as proton tautomers
- proton transfer such as keto-enol and imine-enamine, lactam-lactam isomerizations .
- the compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof.
- isotopic derivative refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass.
- isotopes that can be incorporated into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, such as 2 H (deuterium, D), respectively, 3 H (tritium, T), 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 32 p, 33 p, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 125 I, 129 I and 131 I, etc., preferably deuterium.
- deuterated drugs Compared with non-deuterated drugs, deuterated drugs have the advantages of reducing toxic and side effects, increasing drug stability, enhancing curative effect, and prolonging the biological half-life of drugs. All transformations of the isotopic composition of the compounds of the present disclosure, whether radioactive or not, are included within the scope of the present disclosure.
- Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom, wherein the replacement of deuterium can be partial or complete, and a partial replacement of deuterium means that at least one hydrogen is replaced by at least one deuterium.
- Optionally or “optionally” means that the subsequently described event or circumstance can, but need not, occur, and that the description includes instances where the event or circumstance occurs or instances where it does not.
- “optionally substituted with halogen or cyano” means that halogen or cyano may but need not be present, and the description includes the case where the alkyl is substituted with halogen or cyano and the alkyl is not substituted with halogen and cyano situation.
- Substituted means that one or more hydrogen atoms in a group, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms, independently of one another, are substituted by the corresponding number of substituents.
- a person skilled in the art can determine possible or impossible substitutions (either experimentally or theoretically) without undue effort.
- amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
- “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as pharmaceutically acceptable carriers and excipients .
- the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the present disclosure, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals, and have due biological activity. The salts can be prepared separately during the final isolation and purification of the compounds, or by reacting a suitable group with a suitable base or acid.
- Bases commonly used to form pharmaceutically acceptable salts include inorganic bases such as sodium hydroxide and potassium hydroxide, and organic bases such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids as well as organic acids.
- the term "therapeutically effective amount” refers to an amount of the drug or agent sufficient to achieve, or at least partially achieve, the desired effect.
- the determination of the therapeutically effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance, and the appropriate therapeutically effective amount in each case can be determined by those skilled in the art based on routine experiments.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with patient tissue without undue toxicity, irritation, allergic response or Other problems or complications with a reasonable benefit/risk ratio and are effective for the intended use.
- the present disclosure provides a preparation method of a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IA) or its salt is subjected to deprotection reaction under alkaline or microwave conditions to obtain the compound of general formula (I) or its pharmaceutically acceptable salt;
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Ring A , Ring B, G1 , G2, G6 , G7, R', Ra , p and q are as defined in general formula (I).
- the present disclosure provides a preparation method of a compound represented by general formula (II) or (III) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IIA) or its salt is subjected to deprotection reaction under basic or microwave conditions to obtain the compound of general formula (II) or its pharmaceutically acceptable salt; or
- the compound of general formula (IIIA) or its salt is subjected to deprotection reaction under alkaline or microwave conditions to obtain the compound of general formula (III) or its pharmaceutically acceptable salt;
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Rings A , G1 , G2, G3 , G5, G6 , G7 , R', R4a , R4b , Rq , R, n and q are as in general formula (II) or (III) definition.
- the present disclosure provides a preparation method of a compound represented by general formula (IV) or (V) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IVA) or its salt is subjected to deprotection reaction under basic or microwave conditions to obtain the compound of general formula (IV) or its pharmaceutically acceptable salt; or
- the compound of general formula (VA) or its salt is subjected to deprotection reaction under alkaline or microwave conditions to obtain the compound of general formula (V) or its pharmaceutically acceptable salt;
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Rings A , G1 , R2, R3 , R5 , G6 , G7, R', R4a , R4b , Rq , R, n and q are as in general formula (IV) or (V) definition.
- the present disclosure provides a preparation method of a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (VIA) or its salt is subjected to deprotection reaction under alkaline or microwave conditions to obtain the compound of general formula (VI) or its pharmaceutically acceptable salt;
- R w is an amino protecting group; preferably Ts;
- R 0 is a hydrogen atom
- Ring A , Ring B, Rd , Re , G1 , G2, G6 , G7, Ra , R', t and p are as defined in general formula (VI).
- the present disclosure provides a preparation method of a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (VIA') or its salt is acylated with general formula (VIB) or its salt in the presence of basic conditions and a condensing agent to obtain the compound of general formula (VI) or its pharmaceutically acceptable salt ;
- Ring A , Ring B, Rd , Re , G1 , G2, G6 , G7, Ra , R0 , R', t and p are as defined in general formula (VI).
- the present disclosure provides a preparation method of a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising:
- Ring A , Ring B, Rd , Re , G1 , G2, G6 , G7, Ra , R0 , R', t and p are as defined in general formula (VI).
- the reagents that provide basic conditions in the above synthesis scheme include organic bases and inorganic bases, and the organic bases include but are not limited to triethylamine, pyridine, N,N-diisopropylethylamine, n-butyllithium, Lithium diisopropylamide, tetrahydrofuran solution of lithium diisopropylamide, sodium acetate, potassium acetate, sodium tert-butoxide, potassium tert-butoxide, lithium bis(trimethylsilyl)amide, bis(trimethyl) Silicon) Lithium Lithium Tetrahydrofuran solution or 1,8-diazabicycloundec-7-ene
- the inorganic bases include but are not limited to sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate , sodium hydroxide, lithium hydroxide and potassium hydroxide;
- the reagent for deprotection reaction to provide alkaline conditions is preferably sodium hydroxide;
- the condensing agents described in the above synthesis scheme include but are not limited to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroborate, 1-hydroxybenzotriazole , 1-Hydroxy-7-azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate (HBTU), 2-(7-azo Nitrobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU), benzotriazole-1-yloxytris(dimethylamino)phosphonium Hexafluorophosphate or be
- the reaction of the above steps is preferably carried out in a solvent, and the solvent used includes but is not limited to: pyridine, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, Ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromo Ethane and mixtures thereof.
- the solvent used includes but is not limited to: pyridine, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, Ethyl acetate, n-hex
- the reaction temperature of the above microwave reaction is 50-180°C, preferably 100°C.
- the reaction time of the above microwave reaction is 0.5-4 hours; preferably 2 hours.
- NMR nuclear magnetic resonance
- MS mass spectrometry
- MS was measured with a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
- HPLC High Performance Liquid Chromatography
- Chiral HPLC analysis was determined using an Agilent 1260 DAD high performance liquid chromatograph.
- HPLC preparations used Waters 2767, Waters 2767-SQ Detector2, Shimadzu LC-20AP and Gilson-281 preparative chromatographs.
- the CombiFlash rapid preparation instrument uses Combiflash Rf200 (TELEDYNE ISCO).
- the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the size of the silica gel plate used for thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm, and the size of the TLC separation and purification products is 0.4mm ⁇ 0.5mm.
- Silica gel column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
- the average inhibition rate and IC 50 value of kinases were measured with NovoStar microplate reader (BMG, Germany).
- the known starting materials of the present disclosure can be synthesized using or according to methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Darui chemical companies.
- reaction can be carried out in an argon atmosphere or a nitrogen atmosphere.
- Argon or nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon with a volume of about 1 L.
- Hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon with a volume of about 1 L.
- the pressure hydrogenation reaction uses Parr 3916EKX hydrogenation apparatus and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenation apparatus.
- the hydrogenation reaction is usually evacuated and filled with hydrogen, and the operation is repeated 3 times.
- the microwave reaction used a CEM Discover-S 908860 microwave reactor.
- the solution refers to an aqueous solution.
- reaction temperature is room temperature, which is 20°C to 30°C.
- the monitoring of the reaction progress in the embodiment adopts thin layer chromatography (TLC), the developing solvent used in the reaction, the eluent system of the column chromatography used for purifying the compound and the developing solvent system of the thin layer chromatography method include: A: Dichloromethane/methanol system, B: n-hexane/ethyl acetate system, C: n-hexane/dichloromethane system, D: ethyl acetate/dichloromethane/n-hexane, the volume ratio of the solvent varies according to the polarity of the compound For adjustment, a small amount of basic or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
- TLC thin layer chromatography
- the microwave was reacted at 100 ° C for 2 hours, and the reaction solution was concentrated under reduced pressure and then subjected to high performance liquid chromatography (Waters-2545, chromatographic column: SharpSil-T C18, 30*150mm, 5 ⁇ m; mobile phase: water (10mmol/L) ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 25%-50%, flow rate: 30 mL/min) was purified to give the title compound 2 (1.1 mg, yield: 5%).
- the title compound 5e (500 mg, yield: 87.7%) was obtained by using the third to seventh steps of the synthetic route in Example 1, and replacing the starting compound 1d in the third step with compound 5d.
- Test example 1 HPK1 enzyme activity detection (ADP-Glo method)
- ADP-Glo Kinase Detection Kit including ADP-Glo Reagent and Kinase Detection Reagent (Promega, V9101)
- BSA bovine serum albumin
- MBP Dephosphorylated MBP
- Detection buffer 40 mM Tris-HCl buffer, 7.5; 20 mM MgCl 2 ; 0.1 mg/mL BSA; 50 ⁇ M DTT;
- HPK1 enzyme solution The detection buffer is prepared as HPK1 enzyme solution with a final concentration of 1.5ng/ ⁇ L;
- Test Example 2 Detection of SLP76 protein phosphorylation in Jurkat cells (HTRF method)
- FBS Fetal bovine serum
- CD3 Antibody, anti-human, pure functional grade CD3 Antibody, anti-human, pure-functional grade
- Jurkat E6-1 cells were purchased from the American Type Culture Collection Center (ATCC, TIB-152) and cultured in RPMI1640 medium (10% FBS). Cell culture density was maintained at 2 x 10 5 to 2 x 10 6 cells/mL, and passaged 2-3 times a week.
- Test compounds were dissolved in DMSO to 5 mM.
Abstract
La présente invention concerne un composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine. Plus particulièrement, la présente invention concerne un composé tétracyclique fusionné tel que représenté par la formule générale (I), son procédé de préparation, une composition pharmaceutique contenant le composé, et son utilisation en tant qu'agent thérapeutique, en particulier l'utilisation de celui-ci dans la préparation d'un médicament pour l'inhibition de HPK1, les groupes dans la formule générale (I) étant tels que définis dans la description.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280021238.5A CN116981666A (zh) | 2021-03-26 | 2022-03-25 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110325717 | 2021-03-26 | ||
CN202110325717.3 | 2021-03-26 | ||
CN202110602492 | 2021-05-31 | ||
CN202110602492.1 | 2021-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022199676A1 true WO2022199676A1 (fr) | 2022-09-29 |
Family
ID=83396354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/082894 WO2022199676A1 (fr) | 2021-03-26 | 2022-03-25 | Composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116981666A (fr) |
WO (1) | WO2022199676A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107922431A (zh) * | 2015-06-25 | 2018-04-17 | 大学健康网络 | Hpk1抑制剂及其使用方法 |
CN109923114A (zh) * | 2016-09-09 | 2019-06-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
WO2020103896A1 (fr) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines utilisés en tant qu'inhibiteur de hpk1 et leurs utilisations |
WO2021000925A1 (fr) * | 2019-07-04 | 2021-01-07 | Beigene, Ltd. | Pyrrolo[2, 3-b]pyrazines utilisées en tant qu'inhibiteur de hpk1 et leur utilisation |
CN112243439A (zh) * | 2018-06-13 | 2021-01-19 | 百济神州有限公司 | 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途 |
CN112239473A (zh) * | 2019-07-17 | 2021-01-19 | 百济神州(北京)生物科技有限公司 | 作为hpk1抑制剂的三环化合物的制备方法 |
-
2022
- 2022-03-25 WO PCT/CN2022/082894 patent/WO2022199676A1/fr active Application Filing
- 2022-03-25 CN CN202280021238.5A patent/CN116981666A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107922431A (zh) * | 2015-06-25 | 2018-04-17 | 大学健康网络 | Hpk1抑制剂及其使用方法 |
CN109923114A (zh) * | 2016-09-09 | 2019-06-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
CN112243439A (zh) * | 2018-06-13 | 2021-01-19 | 百济神州有限公司 | 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途 |
WO2020103896A1 (fr) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines utilisés en tant qu'inhibiteur de hpk1 et leurs utilisations |
WO2021000925A1 (fr) * | 2019-07-04 | 2021-01-07 | Beigene, Ltd. | Pyrrolo[2, 3-b]pyrazines utilisées en tant qu'inhibiteur de hpk1 et leur utilisation |
CN112239473A (zh) * | 2019-07-17 | 2021-01-19 | 百济神州(北京)生物科技有限公司 | 作为hpk1抑制剂的三环化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN116981666A (zh) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020156311A1 (fr) | Inhibiteur de dérivé de pyridazine, son procédé de préparation et son utilisation | |
WO2016169421A1 (fr) | Dérivé imidazo isoindole, méthode de préparation correspondante et utilisation médicale correspondante | |
WO2022268051A1 (fr) | Composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine | |
TWI823959B (zh) | 吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
WO2020200069A1 (fr) | Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine | |
WO2022247816A1 (fr) | Composé hétérocyclique contenant de l'azote, son procédé de préparation et son application dans des médicaments | |
WO2022228543A1 (fr) | Composé cyclique ponté, son procédé de préparation et son utilisation en médecine | |
WO2021098811A1 (fr) | Dérivé pyrazolo-hétéroaryl, son procédé de préparation et son utilisation médicale | |
WO2023274397A1 (fr) | Inhibiteur de cdk2, son procédé de préparation et son utilisation | |
CN114907377A (zh) | 稠合四环类化合物、其制备方法及其在医药上的应用 | |
WO2020192750A1 (fr) | Dérivé thiénohétérocyclique, son procédé de préparation et son utilisation médicale | |
WO2022017365A1 (fr) | Dérivé d'isoindoline contenant du soufre, son procédé de préparation et son utilisation médicale | |
WO2020034987A1 (fr) | Promédicament renfermant un dérivé de glucuronide en tant qu'inhibiteur jak, son procédé de préparation et ses applications | |
WO2023072297A1 (fr) | Composé tétracyclique contenant de l'azote, son procédé de préparation et son utilisation en médecine | |
CN112996783B (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
CN113429440B (zh) | 一种螺环化合物的前药、其制备方法及其在医药上的应用 | |
TW202241872A (zh) | 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用 | |
WO2022199676A1 (fr) | Composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine | |
CN114805400A (zh) | 二氢嘌呤硫酮类衍生物、其制备方法及其在医药上的应用 | |
WO2021233371A1 (fr) | Composé fonctionnant comme inhibiteur de protéine de bromodomaine, et composition | |
CN115073472A (zh) | 稠合二环类化合物、其制备方法及其在医药上的应用 | |
WO2022007924A1 (fr) | Dérivé oxa-azabicyclique, son procédé de préparation et son utilisation médicale | |
WO2023109540A1 (fr) | Composé hétérocyclique ayant une activité inhibitrice de kinase akt, son procédé de préparation et son utilisation médicale | |
WO2022022630A1 (fr) | Dérivé oxa-azaspiro, son procédé de préparation et son utilisation pharmaceutique | |
WO2022166810A1 (fr) | Dérivé azatricyclique condensé, son procédé de préparation et son utilisation en médecine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22774330 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280021238.5 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22774330 Country of ref document: EP Kind code of ref document: A1 |